AFR - FEB 6 2025 - Joanne Tran (Markets Reporter)
Stephen Butel is the portfolio manager of Platypus Asset Management Australian Equities Fund. The Sydney-based firm oversees about $5.5 billion in assets.Which stock in the fund do you think is most undervalued by the market and why?
Neuren Pharmaceuticals is a biotech that has the only US Food and Drug Administration-approved treatment, Daybue, for Rett syndrome, which is a rare neurodevelopmental disease that impacts children. In addition, the company has a catalogue of intellectual property to treat several other orphan indications.
What sets Neuren apart from many earlier-stage peers is that it has significant cash on its balance sheet and is generating significant free cash from Daybue royalties. This will allow it to commercialise its existing IP catalogue for new indications that will generate significant value for shareholders.
AFR - FEB 6 2025 - Joanne Tran (Markets Reporter)Stephen Butel...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |